Trial Profile
A Euglycaemic Clamp Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of a Bolus Dose of BioChaperone® Insulin Lispro, Fiasp® and NovoRapid® by an Insulin Pump
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin lispro (Primary) ; Insulin aspart
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Adocia
- 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 11 Dec 2017 Status changed from recruiting to completed.
- 06 Dec 2017 Primary endpoint has been met. (AUCGIR(0-60min)[ Time Frame: 60 minutes ] (Insulin-lispro Vs. Insulin aspart (Novolog))), according to an Adocia media release.